A股異動 | 新諾威漲近6% 2022年淨利預增73%-103%
格隆匯1月10日丨新諾威(300765.SZ)漲5.98%,報17.38元,總市值108億元。新諾威9日發佈業績預吿,預計2022年歸母淨利6.8億元-8億元,比上年同期(重組後)增長72.93%-103.44%。報吿期內,咖啡因價格上漲及銷售數量增加,咖啡因類產品銷售收入及毛利水平均大幅提升,帶動公司整體業績快速增長。另外,石藥聖雪的併入,進一步完善了公司功能性原料業務板塊,公司經營規模和盈利能力得到進一步提高。此外,隨着“陽康”人羣的增加,一些康復後“進補”類消費品開始熱銷。柑橘橙類、蛋白粉、維生素、益生菌等銷售量近期大幅上漲。 新諾威先前表示,隨着近期防疫新政策的實施,特別是2022年12月以來,公司維生素類保健食品市場需求出現了明顯上升,出現供不應求的情況。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.